Short answer
Orthofix Medical Inc. (OFIX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $208M (up 1.1% year over year) with net income of −$6M.
Q3 2026 key financials · XBRL
- Revenue
- $208M
- +1.1% YoY · −1.5% QoQ
- Net income
- −$6M
- +73.4% YoY · +61.6% QoQ
- Operating margin
- 0.7%
- Gross margin
- 70.5%
- EPS (diluted)
- −$0.15
- +73.7% YoY · +60.5% QoQ
Source: XBRL data from the Orthofix Medical Inc. (OFIX) Q3 2026 10-Q on SEC EDGAR. USD.
Orthofix Medical Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $207.9M, up 1.1% YoY from $205.6M
- Operating margin 0.7% vs (8.3%) YoY, net loss margin (2.9%) vs (11.1%)
- Best segment Global Limb Reconstruction, $36.4M, up 8.5%; worst Spinal Implants, Biologics and Enabling Technologies, $107.4M, down 1.1%
- Cash $86.9M vs $85.1M at December 31, 2025; nine-month operating cash flow $(23.5)M
- $65.0M Term B Loan funded; FDA reclassification headwind, heightened competition and pricing pressure for bone stimulators
Risk Factors
- Regulatory risk: FDA reclassification from Class III to Class II lowers entry barriers for bone growth stimulators
- Competitive risk: New entrants could create pricing pressure and erode Orthofix’s market share
- Operating risk: Higher research, clinical, marketing, and surveillance spending could reduce margins
- Market risk: Increased competitor promotion could reduce demand for Orthofix products
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Orthofix Medical Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.